Study: Tocomin® natural full spectrum palm tocotrienol complex suppresses angiogenesis

August 8th, 2007 – Edison, New Jersey – Carotech Ltd, the largest and leading manufacturer of premium quality natural full spectrum palm tocotrienol complex (Tocomin®) and natural palm mixed carotene complex (Caromin®), is pleased to announce the publication of the latest research study on Tocomin® and its potent effect in preventing the formation of new blood vessels.

Published in the August issue of the Journal of Nutrition (137(8), 1938–1943), Japanese researchers from the Tohoku University and Nippon Medical School, Tokyo showed that natural full spectrum palm tocotrienol complex (in the form of Tocomin® 50%, supplied by Carotech Ltd) suppressed in vivo angiogenesis in bovine aortic endothelial cells and human umbilical vein endothelial cells (HUVEC). The researchers investigated tocotrienol’s antiangiogenic properties using two well-characterized angiogenic mouse models—the mouse dorsal air sac (DAS) assay and the chick embryo chorioallantoic membrane (CAM) assay.

In the DAS assay, dietary supplementation of 10 mg of Tocomin® 50% per day clearly and significantly prevented the increased in neovascularization by more than 40% in tumor cell-implanted mice, compared to control. Similarly, in the CAM assay, Tocomin® inhibited new blood vessel formation on the growing CAM, resulting in avascular zone. Cell-culture studies revealed tocotrienol significantly reduced fibroblast growth factor-induced proliferation, migration and tube formation in HUVEC.

The researchers found no negative effects in preexisting vessels treated with Tocomin® 50% - indicating that normal blood vessels are not affected by tocotrienols. Another interesting observation was is that the regular tocopherol (alpha tocopherol) showed no angiogenic inhibition effect, suggesting that the three double bonds in the unsaturated side chain of tocotrienol play an important factor in conferring tocotrienol its potent antiangiogenic effect.

The study was demonstrated that the angiogenic inhibitory effect of Tocomin® was associated with changes in the phosphatidylinositol-3 kinase (PI3K/PDK/Akt) signaling as well as apoptosis induction in the endothelial cells.
The Japanese researchers led by Dr. Kiyotaka Nagakawa concluded that tocotrienol has potential as a potent therapeutic dietary supplement for preventing angiogenic disorders especially in inhibiting tumour growth.
Carotech Inc, is a wholly owned subsidiary of Carotech Bhd, Malaysia. Carotech, a public listed company in Malaysia (Malaysian Securities Exchange Board under the high-technology / high growth, MESDAQ Board), is the largest producer of tocotrienol in the world via its patented technology. Carotech Bhd is a subsidiary of Hovid Bhd., one of the largest GMP-certified pharmaceutical companies in Malaysia.

For more information about Tocomin®, visit or Tocomin is a registered trademark of Carotech Inc.
WH Leong
Vice President
Carotech Inc
732 906 1901
[email protected] or [email protected]

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.